Difference between revisions of "Healthcare AI Use Cases"

From PatientRecovery
Jump to: navigation, search
 
(26 intermediate revisions by one user not shown)
Line 1: Line 1:
 
==ClosedLoop AI Use Cases==
 
==ClosedLoop AI Use Cases==
Hospitals <br>
+
Providers & ACOs <br>
* [https://news.mit.edu/2020/closedloop-ai-predictive-health-care-0619?utm_source=miragenews&utm_medium=miragenews&utm_campaign=news Help determine which patients are most likely to miss appointments, acquire infections like sepsis, benefit from periodic check ups]
+
* [https://news.mit.edu/2020/closedloop-ai-predictive-health-care-0619?utm_source=miragenews&utm_medium=miragenews&utm_campaign=news '''Appointment No-Shows''' - Predict patients most likely to miss appointments]
Health Insurers <br>
+
* [https://news.mit.edu/2020/closedloop-ai-predictive-health-care-0619?utm_source=miragenews&utm_medium=miragenews&utm_campaign=news Predict patients most likely to acquire infections like sepsis]
* [https://news.mit.edu/2020/closedloop-ai-predictive-health-care-0619?utm_source=miragenews&utm_medium=miragenews&utm_campaign=news Help make population-level predictions around things like patient readmissions and the onset or progression of chronic diseases.]
+
* [https://news.mit.edu/2020/closedloop-ai-predictive-health-care-0619?utm_source=miragenews&utm_medium=miragenews&utm_campaign=news Predict patients most likely to benefit from periodic check ups]
 +
* Leakage - Network Integrity - Out of Network
 +
* Total Risk:  Who will be my most expensive patients this year
 +
* ED Over-Utilization:  Which of my patients would most benefit from establishing a relationship with a primary care provider?
 +
* Readmissions:  Which patients are most likely to be readmitted to the hospital?
 +
* Transportation:  Which patients are most likely to need help with transportation in order to make it to their appointments
 +
* Rising Risk:  Which patients are likely to see large increases in their overall health risk over the next 30/60 days?
 +
* Chronic Disease:  Which patients are most likely to develop or progress in the severity of a chronic disease
 +
* Medication Adherence:  Which patients are most likely to be noncompliant with medications?
 +
 
 +
Payers and Health Plans <br>
 +
* Risk Adjustment - Suspect Diagnosis
 +
* [https://closedloop.ai/preventable-hospitalizations/ Preventable Hospitalizations]
 +
* [https://closedloop.ai/readmissions/ Readmissions] - [https://news.mit.edu/2020/closedloop-ai-predictive-health-care-0619?utm_source=miragenews&utm_medium=miragenews&utm_campaign=news Predict patient readmissions]
 +
* [https://closedloop.ai/chronic-disease/ Chronic Disease Onset and Progression] - [https://news.mit.edu/2020/closedloop-ai-predictive-health-care-0619?utm_source=miragenews&utm_medium=miragenews&utm_campaign=news Predict onset or progression of chronic diseases.]
 +
* [https://closedloop.ai/total-risk/ Patients with highest overall risk in the next 6 months or year]
 +
* Trend:  Which members are likely to see large increases in their overall health risk over the next three to six months?
 +
* Readmissions:  Which members are most likely to be readmitted to the hospital?
 +
* Medication Adherence:  Which members are most likely to be noncompliant with medication plans?
 +
* Palliative Care:  Which members are most likely to benefit from discussions with a palliative care specialist?
 +
* ED Over-Utilization:  Which members are most likely to benefit from establishing a relationship with a primary care provider?
 +
* Disenrollment:  Which members will most likely to disenroll?
 +
* Fraud:  How do new data sources allow health plans to spot fraud sooner?
 +
* Payment Integrity:  How can AI help ensure proper reimbursement?
 +
 
 +
Pharma & Life Science <br>
 +
* Biomarkers:  Which patients will have an increased success rate based on biological factors?
 +
* Drug-Combinations:  Which drug combinations are most likely to be successful?
 +
* Segmentation:  Which groups of patients respond differently to treatment?
 +
* Strategy:  Which subpopulations should be included/excluded based off of predicted success rates?
 +
* Responsive:  Which patients are responding to treatment?
 +
* Events:  Which patients are most likely to experience adverse reactions?
 +
* Effectiveness:  How will clinical trial results translate into real world effectiveness?
 +
* Value:  What improvement in outcomes will a new treatment generate over existing therapies?
 +
* Switching:  Which factors are most relevant in understanding which patients switch drugs?
 +
* Marketing:  Which physicians can we market to?
 +
 
 +
 
 +
Other <br>
 +
* [https://www.beckershospitalreview.com/artificial-intelligence/ge-university-hospitals-cleveland-partner-on-ai-lung-imaging-tech.html '''Identify patients' with collapsed lungs''' - artificial intelligence-enabled mobile X-ray system flags images of patients who need immediate intercession, ensuring that patients with collapsed lungs receive more timely care. (7/8/20)]
 +
*  [https://www.beckershospitalreview.com/artificial-intelligence/mayo-clinic-to-implement-ai-powered-predictive-patient-triage-platform.html '''Predicts patients' hospitalization risk and triages them to appropriate care''' - uses AI tech, EHR data and a questionnaire to perform clinical intake of patients visiting ER, Urgent Care or Home (6/30/20)]
 +
* [https://jamanetwork.com/journals/jama/fullarticle/2665774 Diagnosed breast cancer at a higher rate than 11 pathologists. AI model using algorithms and deep learning (12/12/17)]
 +
* Reducing cost of Rx at a system level without sacrificing quality
 +
 
 +
* [https://www.kensci.com/solutions/ops/ Emergency Department Demand Prediction]
 +
* [https://www.kensci.com/solutions/ops/ Emergency Department Utilization Prediction]
 +
* [https://www.kensci.com/solutions/ops/ Length of Stay Prediction]

Latest revision as of 10:27, 10 July 2020

ClosedLoop AI Use Cases

Providers & ACOs

Payers and Health Plans

Pharma & Life Science

  • Biomarkers: Which patients will have an increased success rate based on biological factors?
  • Drug-Combinations: Which drug combinations are most likely to be successful?
  • Segmentation: Which groups of patients respond differently to treatment?
  • Strategy: Which subpopulations should be included/excluded based off of predicted success rates?
  • Responsive: Which patients are responding to treatment?
  • Events: Which patients are most likely to experience adverse reactions?
  • Effectiveness: How will clinical trial results translate into real world effectiveness?
  • Value: What improvement in outcomes will a new treatment generate over existing therapies?
  • Switching: Which factors are most relevant in understanding which patients switch drugs?
  • Marketing: Which physicians can we market to?


Other